Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P310. Added value of anti CBir-1 antibodies to differentiate IBD unclassified from ulcerative colitis
Authors:

O. Ben-Bassat1, W. Xu2, J.M. Stempak3, M.S. Silverberg1, G. Van Assche1, 1Mount Sinai Hospital, Gastroenterology, Toronto, Canada, 2University of Toronto, Dalla Lana School of Public Health, Toronto, Canada, 3Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases, Toronto, Canada

P310. Late onset inflammatory bowel disease – View from a regional hospital
P310. Safety profile of anti‑TNF therapy in Brazilian IBD patients: Are there differences between infliximab and adalimumab?
P310

Systematic review: The financial burden of surgical complications in patients with ulcerative colitis

Authors:

J.O. Lindsay1, L. Peyrin-Biroulet*2, A.S. Patel3, A. Bergman4

1The Royal London Hospital, Barts Health NHS Trust Department of Gastroenterology, London, United Kingdom, 2Nancy University Hospital, Université de Lorraine, Inserm U954 and Department of Gastroenterology, Vandouvre-les-Nancy, France, 3Abacus International, Systematic Review, Bicester, United Kingdom, 4Takeda Pharmaceuticals International GmbH, EUCAN (IBD), Glattpark-Opfikon, Switzerland

P311.

Thiopurine metabolite monitoring and allopurinol combination therapy: current utilisation and influence on Australian gastroenterology IBD practice

Authors:

K.C.P. Sze, W.S.W. Ng, S.J. Connor, Liverpool Hospital & University of NSW, Dept. of Gastroenterology, Sydney, Australia

P311. Adalimumab treatment is associated with improved quality of life in pediatric Crohn's disease
Authors:

J.C. Escher1, G. Veereman-Wauters2, W. Crandall3, F.M. Ruemmele4, A. Lazar5, M. Yang5, M. Skup5, P.M. Mulani5, J. Chao5, R.B. Thakkar5, J. Hyams6, 1Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands, 2UZ Brussels, Brussels, Belgium, 3Nationwide Children's Hospital, Columbus, OH, United States, 4Hôpital Necker-Enfants Malades, Paris, France, 5Abbott Laboratories, Abbott Park, IL, United States, 6Connecticut Children's Medical Center, Hartford, CT, United States

P311. Azathioprine and allopurinol co-therapy for IBD patients is a safe and effective treatment option in the district general hospital setting
P311. Clinical presentation and risk factors for surgery in Crohn's disease: Analysis of 173 patients in China
P311

Measurement of functional blocade of TNF-alpha by anti-TNF agents is a stronger predictor than trough levels and anti-drug antibodies: 2-year prospective clinical data

Authors:

P. Juillerat*1, P. Andrew2, J. Macpherson2, J. Cahenzli2, N. Patuto2, E. Slack2, F. Seibold1, K.D. McCoy2, A.J. Macpherson1, 2

1Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, 2University Bern, Maurice E Müller Laboratories, Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Bern, Switzerland

P312.

Thiopurine metabolite testing in inflammatory bowel disease

Authors:

R. Goldberg1, G. Cunningham2, G. Moore1, J. Schulberg2, S. Brown2, W. Connell2, M. Lust2, M. Kamm2, S. Bell2, 1Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia, 2St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia

P312. Acutec: differential diagnosis using computed tomography
Authors:

L. Plastaras1, S. Koch2, L. Vuitton1, E. Nedeva3, V. di Martino4, E. Delabrousse3, 1University Hospital of Besançon, Gastroenterology, Besançon, France, 2University Hospital of Besançon, Gastroenterology, Besançon, France, 3University Hospital of Besançon, Radiology, Besançon, France, 4University Hospital of Besançon, Hepatology, Besançon, France

P312. Cognitive-behavioural therapy (CBT) to manage inflammatory bowel disease (IBD): Preliminary findings
P312. Quick schedule and double dose vaccination against hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD)
P312

Evolution of the Lemann index in Crohn's disease: a retrospective study

Authors:

N. Duveau*1, M. Azahaf1, H. Panchal2, M. Nachury1, J.F. Colombel2, B. Pariente1

1CHU de Lille, Department of Gastroenterology, Lille, France, 2Icahn School of Medicine at Mount Sinai Hospital, Gastroenterology, New York, NY, United States

P313.

The use of sirolimus for refractory inflammatory bowel disease: A single centre experience

Authors:

M. Mutalib, S. Blackstock, S. Chadokufa, B. Huggett, N. Shah, M. Elawad, F. Kiparissi, K. Lindley, Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom

P313. A composite serological panel predicts burden of inflammation in Crohn's disease
Authors:

O. Ben-Bassat1, S. Lockton2, F. Princen2, J.M. Stempak3, G. Van Assche1, S. Singh2, M.S. Silverberg1, 1Mount Sinai Hospital, Gastroenterology, Toronto, Canada, 2Prometheus Labs, San Diego, United States, 3Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases, Toronto, Canada

P313. Adherence to treatment in Latvian patients with inflammatory bowel disease
P313. Mucosal healing in Crohn's disease: Prognostic significance and relationship to treatment
P313

Medication use and its perception by female inflammatory bowel disease patients.

Authors:

S. Chetcuti Zammit1, M. Caruana1, K.H. Katsanos2, G.J. Mantzaris3, M. Cesarini4, U. Kopylov5, L. Zammit1, P. Ellul*1

1Mater Dei Hospital, Department of Gastroenterology, Msida, Malta, 2University of Ioannina School of Medical Sciences, Department of Internal Medicine, Medical School, Ioannina, Greece, 3Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Department of Gastroenterology, Athens, Greece, 4Sapienza University of Rome, Dipartimento di Medicina Interna e Specialità' Mediche, Rome, Italy, 5Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel

Medication% Number of patients
5-ASA66%
Steroids6.44%
Azathioprine22.3%
Infliximab20.2%
Adalimumab7.30%
Methotrexate1.29%
6-Mercaptopurine1.29%
Sulfasalazine1.29%
P314.

The type of iron deficiency anaemia, but not the underlying disease, predicts intestinal iron absorption in IBD patients

Authors:

M. Wiesenthal1, A. Dignass2, F. Hartmann1, J. Stein1, 1Crohn Colitis Center, DGD Krankenhaus Sachsenhausen, Frankfurt, Germany, 2Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany